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ular filtration barrier, and improved experimental tools. Therapeutically we are also more able to target specific molecules, for example by monoclonal antibody treatments. In this context, the report of the effects of TNF-α on podocytes is instructive. This tells us that this cytokine could have directly deleterious effects on podocytes in vivo, and that this effect can be targeted clinically, potentially halting or reversing the disease process. As with all thought provoking research, this raises several interesting questions. Is TNF-α the elusive 'factor' or is it one of several? Is it directly affecting the glomerular filtration barrier, or modulating the immune response? And could this technique be used as a cellbased assay for disease activity? This report adds to the growing list of candidates that need to be tested in a wider population of well phenotyped patients with SRNS.
Keywords Steroid resistant nephrotic syndrome . Focal segmental glomerulosclerosis . Plasma factor . TNF-α . Podocyte . Proteinuria . Cytokine . Cytoskeleton
